Healthcare Services

Chemotherapy-Induced Anemia Market Outlook 2026–2030 Exploring New Business Opportunities

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Chemotherapy-Induced Anemia Market Over The 2026–2030 Period?

The market for chemotherapy-induced anemia has experienced significant expansion in recent years. It is projected to increase from $2.81 billion in 2025 to $3.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This historical growth can be attributed to several factors including the rising adoption of intensive chemotherapy regimens, an increase in the prevalence of treatment-related anemia, the expansion of oncology treatment centers, improved accessibility to blood transfusion services, and the availability of supportive cancer care therapies.

The chemotherapy-induced anemia market is projected to expand significantly over the coming years, with forecasts indicating it will reach $4.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.1%. This expansion is attributed to a heightened demand for long-acting anemia solutions, a greater emphasis on reducing transfusion reliance, the broadening of personalized oncology services, the increasing uptake of home-based care options, and improvements in anemia management medications. Key developments anticipated during this period involve the wider acceptance of erythropoiesis-stimulating agents, the increased application of tailored anemia management strategies, a growing inclination towards early intervention methods, the enlargement of outpatient facilities for anemia treatment, and a sharpened emphasis on improving patient quality of life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12513&type=smp

What Underlying Factors Are Accelerating The Growth Of The Chemotherapy-Induced Anemia Market?

The widespread occurrence of cancer and anemia is anticipated to boost the expansion of the chemotherapy-induced anemia market in the future. Cancer is characterized by the uncontrolled proliferation of cells and their dissemination to various parts of the body. Among individuals undergoing intensive chemotherapy, with or without concurrent radiation, both cancer itself and chemotherapy-induced anemia (CIA) are commonly observed. Treatments for chemotherapy-induced anemia involve stimulating the production of red blood cells in the bone marrow. For example, in 2023, data from Cancer Research UK, a UK-based independent cancer research organization, indicates that the occurrence of head and neck cancer in the UK is predicted to climb by 3% between 2023 and 2025, whereas fatalities attributed to head and neck cancers are forecast to grow by 12% between 2023 and 2025. Consequently, the substantial presence of cancer and anemia is a key factor propelling the expansion of the chemotherapy-induced anemia market.

How Is The Chemotherapy-Induced Anemia Market Segmented Across Key Categories?

The chemotherapy-induced anemia market covered in this report is segmented –

1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia

2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation

3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers

Subsegments:

1) By Mild Anemia: Hemoglobin Levels 10-12 Grams Per Deciliter (g/dL), Symptomatic Treatments

2) By Moderate Anemia: Hemoglobin Levels 8-10 Grams Per Deciliter (g/dL), Erythropoiesis-stimulating Agents (ESAs), Blood Transfusion Management

3) By Severe Anemia: Hemoglobin Levels 6.5-8 Grams Per Deciliter (g/dL), Intensive ESA Treatments, Frequent Blood Transfusions

4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 Grams Per Deciliter (g/dL), Emergency interventions, Critical Care And Monitoring

How Are Trends Transforming The Chemotherapy-Induced Anemia Market Landscape?

Major companies in the chemotherapy-induced anemia market are concentrating on developing technological advancements, such as Ojjaara (momelotinib), to enhance treatment options and improve patient outcomes for those affected by anemia related to cancer therapies. The name ‘Ojjaara’ is derived from the word ‘Ojaara,’ which suggests a connection to the concept of healing or wellness. For instance, in September 2023, Ojjaara (momelotinib) was developed by GSK (GlaxoSmithKline), an England-based company; it signifies the drug’s purpose as a treatment for myelofibrosis, particularly in patients with anemia. Ojjaara (momelotinib) represents a groundbreaking treatment for myelofibrosis patients experiencing anemia, functioning by inhibiting key pathways to improve blood counts, enhance quality of life, and reduce the need for blood transfusions, making it the first and only therapy specifically indicated for this condition.

Who Are The Dominant Players Shaping The Chemotherapy-Induced Anemia Market Landscape?

Major companies operating in the chemotherapy-induced anemia market are Pfizer Inc., Johnson & Johnson, F. Hoffmann‑La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Fresenius Kabi AG, Biocon Ltd., Vifor Pharma Group, Pharmacosmos A/S, Daiichi Sankyo Company Limited, Bayer AG, Akebia Therapeutics Inc, Otsuka Pharmaceutical Co Ltd, Zydus Lifesciences Ltd, Viatris Inc, Shield Therapeutics plc, Keros Therapeutics Inc

Read the full chemotherapy-induced anemia market report here:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Which Region Is Projected To Dominate The Chemotherapy-Induced Anemia Market During The Forecast Period?

North America was the largest region in the chemotherapy-induced anemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chemotherapy-Induced Anemia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12513&type=smp

Browse Through More Reports Similar to the Global Chemotherapy-Induced Anemia Market 2026, By The Business Research Company

Peripheral Neuropathy Global Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Diabetic Neuropathy Global Market Report

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Neuropathic Pain Global Market Report

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795